IL6 and neoplasm: LPS activates Toll-like receptor 4 (TLR4), leading to NF-κB activation and the subsequent transcription of inflammatory mediators such as IL-6 and TNF-α, thereby fostering chronic low-grade inflammation and tumour progression [85].